Related Experiment Video
Updated: Jun 26, 2026

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
Consequences of the inhibition of Hdm2 expression in human osteosarcoma cells using antisense oligonucleotides
1Department of Oncology, Nucleic Acid Sciences, Novartis Pharma Inc, Basel, Switzerland. thomas.geiger@pharma.novartis.com
Abstract:
The present study was performed to identify a potent and sequence-specific antisense oligonucleotide (ASO), to inhibit Hdm2 expression in human cancer cell lines and to study the downstream consequences. Ten chimeric 2'-O-methoxyethyl (MoE)-modified hemimers were synthesized that targeted various regions from the 5'- to the 3'-end of Hdm2 mRNA. The IC50 of the most potent ASO, NCH-4401, was subsequently determined and compared to the IC50 of a 2'-MoE-modified ASO, with a complete phosphorothioate backbone (NCH-4668), and to a 3 bp mismatched ASO (NCH4529). NCH4401 inhibited Hdm2 expression in SJSA-1 cells with an IC50 of 120 nm, whereas NCH-4668 was less potent with an IC50 of 180 nm. The mismatched control ASO was completely inactive, indicating a sequence-dependent mechanism of action of NCH-4401. NCH4401 was subsequently used to study the consequences of inhibiting Hdm2 expression in human osteosarcoma cells. NCH-4401 completely inhibited Hdm2 protein expression in SJSA-1 cells at a concentration of 300 nm, already 4 h after start of ASO treatment. At an ASO concentration of 300 nM, p53 protein was induced 12.5-fold and p21 was induced 8-fold over background levels, 24 h after start of ASO treatment. The dramatic induction of p53 in SJSA-1 cells prompted us to investigate whether the accumulation of p53 in these cells was followed by induction of apoptosis. However, no signs for apoptosis were detected in SJSA-1 cells, following induction of wild-type p53 using the Yopro method and the induction of caspase-3 activity. SJSA-1 cells were subsequently treated with NCH-4401 at different concentrations in combination with two well-known DNA-damaging agents, i.e. carboplatin and mitomycin C. Apoptosis induction following treatment of cells with DNA-damaging agents and NCH4401 was determined in parallel by measuring caspase-3 activation and uptake of the DNA dye Yopro. Carboplatin and mitomycin C together only slightly induced apoptosis in SJSA-1 cells to a factor of approximately 2-fold, as measured by the induction of caspase-3 activity. The downregulation of Hdm2 expression by NCH4401 did not induce apoptosis on its own and did not potentiate the mitomycin C/carboplatin-induced programmed cell death.
Insights
Researchers identified a potent antisense oligonucleotide (ASO), NCH-4401, that effectively inhibits Hdm2 expression in human cancer cells. This inhibition leads to p53 and p21 induction but does not trigger apoptosis, even when combined with chemotherapy agents.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Hdm2 is a key regulator of p53 stability and function.
- Inhibiting Hdm2 offers a potential therapeutic strategy for cancers with wild-type p53.
- Antisense oligonucleotides (ASOs) provide a targeted approach to modulate gene expression.
Purpose of the Study:
- To identify and characterize a potent, sequence-specific antisense oligonucleotide (ASO) targeting Hdm2 mRNA.
- To investigate the downstream effects of Hdm2 inhibition on p53 pathway activation and apoptosis in human cancer cells.
Main Methods:
- Synthesis and screening of chimeric 2'-O-methoxyethyl (MoE)-modified ASOs targeting Hdm2 mRNA.
- Determination of IC50 values for ASO potency and specificity.
- Assessment of Hdm2 protein levels, p53 and p21 induction, and apoptosis markers (caspase-3 activity, Yopro staining).
Main Results:
- NCH-4401 demonstrated potent and sequence-specific inhibition of Hdm2 expression in SJSA-1 cells (IC50 = 120 nM).
- Hdm2 protein inhibition by NCH-4401 led to significant induction of p53 (12.5-fold) and p21 (8-fold).
- NCH-4401 alone did not induce apoptosis and did not potentiate apoptosis induced by carboplatin or mitomycin C.
Conclusions:
- NCH-4401 is a potent inhibitor of Hdm2 expression with potential therapeutic applications.
- Hdm2 inhibition activates the p53 pathway but does not directly induce apoptosis in osteosarcoma cells.
- Combined Hdm2 inhibition and DNA-damaging chemotherapy does not enhance programmed cell death in this model.

